Mizuho Senior Biotech Analyst Salim Syed highlights key companies in the news he covers heading into the new year
BiotechTV - News
00:00
Cytokinetics' Mycorzo approval
Salim explains Mycorzo's REMS and dosing advantages versus Camzyos and its likely favorable physician uptake.
Play episode from 11:18
Transcript
